Maryland 2024 Regular Session

Maryland House Bill HB736

Introduced
1/29/24  

Caption

Health Insurance and Maryland Medical Assistance Program - Coverage - Opioid Reversal Drugs and Products (NARCAN Price Cap Act)

Impact

The Act will take effect on January 1, 2025, applying to all health policies and contracts issued or renewed after this date. It aligns with existing provisions in Maryland regarding health coverage for opioid-related treatments and highlights the state’s commitment to addressing public health challenges posed by opioid addiction. The integration of naloxone coverage into state health programs and private insurance policies signifies a significant step forward in mitigating the issues related to opioid misuse and overdose deaths in Maryland populations, particularly those most at risk.

Summary

House Bill 736, also known as the NARCAN Price Cap Act, mandates that the Maryland Medical Assistance Program, along with certain insurers and health service plans, offer coverage for nonprescription naloxone hydrochloride and any other FDA-approved product intended for opioid overdose reversal. This legislation is part of a broader effort to combat the ongoing opioid crisis by ensuring accessibility to life-saving medications without imposing significant financial burdens on patients. It establishes a maximum copayment or coinsurance requirement of $10 per package for these products, which aims to alleviate cost barriers that might prevent individuals from obtaining naloxone in urgent situations.

Contention

While proponents of HB 736 argue that the bill is crucial for improving access to naloxone and potentially saving lives during opioid emergencies, critics have raised concerns regarding implementation logistics and the adequacy of funding for the expanded coverage. Some stakeholders worry about the impact on insurance premiums and the potential for increased utilization without adequate support systems in place for individuals at risk of overdose. The discussion surrounding the bill indicates a strong divide on the best approaches to effectively manage the opioid crisis, emphasizing the need for comprehensive strategies that also encompass prevention, treatment, and recovery initiatives.

Companion Bills

MD SB497

Crossfiled Health Insurance and Maryland Medical Assistance Program - Coverage - Opioid Reversal Drugs and Products

Previously Filed As

MD HB1217

Maryland Medical Assistance Program and Health Insurance - Required Coverage for Biomarker Testing

MD SB805

Maryland Medical Assistance Program and Health Insurance – Required Coverage for Biomarker Testing

MD SB75

Insurance and Maryland Medical Assistance Program – Treatment of Alopecia Areata – Coverage Requirements

MD SB954

Opioids - Opioid Restitution Advisory Council and Fund and Overdose Response Program

MD HB571

Opioids - Opioid Restitution Advisory Council and Fund and Overdose Response Program

MD HB111

Maryland Medical Assistance Program, Maryland Children's Health Program, and Workgroup on Low-Income Utility Assistance

MD SB26

Maryland Medical Assistance Program, Maryland Children's Health Program, and Workgroup on Low-Income Utility Assistance

MD HB813

Maryland Medical Assistance Program – Prescription Digital Therapeutics

MD SB460

Maryland Medical Assistance Program – Gender–Affirming Treatment (Trans Health Equity Act)

MD HB283

Maryland Medical Assistance Program - Gender-Affirming Treatment (Trans Health Equity Act)

Similar Bills

No similar bills found.